Covid Rapid Diagnostic Test Market By Test Type (Antigen, Molecular); By Sample Type (Nasal, Saliva); By Format (Cassette, Strip); By Use Setting (Point-of-Care, Home-use); By Distribution Channel (Pharmacies, Online, Institutional Sales); By Regulatory Status (EUA, Fully Approved); By Region – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032
The global Covid Rapid Diagnostic Test Market size was estimated at USD 5,214.79 million in 2025 and is expected to reach USD 7,264.30 million by 2032, growing at a CAGR of 5.68% from 2025 to 2032. Growth is primarily supported by sustained routine testing demand across outpatient care, workplaces, and household self-testing, where rapid turnaround time continues to influence clinical and consumer decisions. Demand is also reinforced by broader test access through retail and digital channels and continued use of rapid diagnostics within respiratory-season protocols across major health systems.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2025
Forecast Period
2026-2032
Covid Rapid Diagnostic Test Market Size 2025
USD 5,214.79 million
Covid Rapid Diagnostic Test Market, CAGR
5.68%
Covid Rapid Diagnostic Test Market Size 2032
USD 7,264.30 million
Key Market Trends & Insights
The Covid Rapid Diagnostic Test Market is projected to expand from USD 5,214.79 million (2025) to USD 7,264.30 million (2032), reflecting a 5.68% CAGR (2025–2032).
North America accounted for 37.90% share in 2025, supported by high testing penetration and established distribution and reimbursement pathways.
Europe held 25.40% share in 2025, reflecting steady institutional demand and public procurement discipline in mature diagnostic markets.
Antigen tests accounted for the largest share of 64.20% in 2025, driven by fast turnaround time and broad scalability for self-testing and point-of-care use.
Nasal sample-based testing accounted for the largest share of 55.60% in 2025, supported by widespread standardization in rapid test workflows and consumer familiarity.
Segment Analysis
Demand patterns in the Covid Rapid Diagnostic Test Market are increasingly shaped by end-user preferences for speed, convenience, and accessible distribution. Rapid tests remain central to decentralized decision-making, including household screening, outpatient triage, and occupational health checks. Product design priorities continue to emphasize usability, clear result interpretation, and dependable performance across common respiratory-season use cases. Buyer behavior also favors trusted brands, consistent availability, and frictionless purchasing through pharmacies and online marketplaces.
Competitive differentiation is frequently built around breadth of product portfolios, regulatory positioning, and manufacturing scale. Suppliers with both professional point-of-care offerings and consumer OTC self-tests tend to capture wider demand cycles across seasonal surges and endemic baseline use. Institutional buyers continue to prioritize supply reliability and validated performance documentation, while consumer channels prioritize convenience, value, and simplicity of instructions.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Antigen accounted for the largest share of 64.20% in 2025. Antigen testing leads because rapid turnaround supports immediate isolation and treatment decisions in outpatient and home settings. Antigen test workflows are typically simpler than lab-based alternatives, enabling broad uptake across pharmacies, workplaces, and home-use scenarios. Antigen tests also align well with large-volume screening needs during seasonal spikes, supporting recurring purchases across retail and institutional channels.
By Sample Type Insights
Nasal accounted for the largest share of 55.60% in 2025. Nasal sampling leads because the approach is widely standardized for rapid testing workflows and is familiar to consumers from prior testing cycles. Nasal swab collection typically fits well with OTC self-test instructions and point-of-care procedures, reducing operational variability in decentralized settings. Nasal sampling also supports repeat testing behavior due to convenience and broad availability of nasal-based kits.
By Format Insights
Covid Rapid Diagnostic Test Market format adoption is largely determined by ease of handling, clarity of result readout, packaging efficiency, and suitability for self-use instructions. Cassette formats are often preferred for consumer clarity and standardized handling, especially where error-reduction is important for home-use adoption. Strip formats may remain relevant in cost-sensitive channels and high-volume programs that prioritize simplified packaging and logistics. Suppliers also use format choices to balance manufacturing throughput with usability requirements across different buyer segments.
By Use Setting Insights
Use-setting dynamics are shaped by access, urgency of results, and frequency of testing needs. Point-of-care demand remains important for rapid triage and immediate decision support in clinics, urgent care, and outpatient settings. Home-use demand is supported by convenience-driven purchasing behavior, especially through pharmacy and online channels. Covid Rapid Diagnostic Test Market suppliers frequently position products across both settings using differentiated packaging, instructions, and channel strategies.
By Distribution Channel Insights
Distribution is increasingly defined by retail reach, digital procurement convenience, and institutional contracting cycles. Pharmacies play a central role in consumer access and replenishment during seasonal demand spikes. Online channels support broader geographic coverage, subscription-like replenishment behavior, and price comparison shopping. Institutional sales remain relevant for employers, schools, and health systems seeking standardized procurement and predictable supply availability.
By Regulatory Status Insights
Regulatory positioning influences product lifecycle planning and buyer confidence. EUA-listed products can remain relevant where emergency mechanisms are applicable, especially during demand spikes and variant-driven waves. Fully approved or cleared products tend to strengthen procurement confidence for long-term planning and standardized purchasing requirements. Covid Rapid Diagnostic Test Market suppliers often use regulatory milestones to reinforce credibility, expand addressable customer segments, and support multi-year contracting discussions.
Covid Rapid Diagnostic Test Market Drivers
Expansion of decentralized testing and self-care behaviors
Decentralized care models continue to support rapid testing adoption across outpatient and home settings. The Covid Rapid Diagnostic Test Market benefits from decision-making needs that favor fast answers at the point of encounter rather than delayed lab confirmation. Household purchasing behavior also supports repeat testing during respiratory-season peaks. Retail access and simplified test instructions help sustain demand beyond emergency-only use patterns.
Institutional readiness and operational screening needs
Workplaces, schools, and care facilities continue to maintain screening protocols for outbreak prevention and operational continuity. The Covid Rapid Diagnostic Test Market is supported by institutional procurement cycles that value rapid turnaround and scalable distribution. Rapid tests fit operational screening because results are immediate and workflows can be executed without specialized lab infrastructure. Suppliers that provide reliable supply and consistent documentation are favored in these procurement settings.
For instance, BD’s Veritor Plus System for Rapid Detection of SARS-CoV-2 & Flu A+B provides digital results in 15 minutes, showed 86.7% positive percent agreement and 99.5% negative percent agreement for SARS-CoV-2, and is supplied in 30-test kits, making it well aligned with organized screening workflows that require speed, scalability, and documentation.
Product accessibility through pharmacies and e-commerce channels
Pharmacies and online channels lower friction for consumers seeking quick access to tests. The Covid Rapid Diagnostic Test Market benefits from strong retail visibility and the ability to purchase tests alongside common respiratory-care products. E-commerce growth also supports access in smaller cities and rural areas where retail assortment may be limited. The combination of omnichannel access and promotional bundles can increase basket size and repeat purchases.
For instance, QuidelOrtho’s QuickVue At-Home OTC COVID-19 Test delivers results in 10 minutes and is authorized for self-testing by individuals aged 14 years and older, or for adult-collected samples from children aged 2 years and older, with asymptomatic use structured as two tests over three days, supporting convenient retail and online purchase for home use.
Portfolio breadth and manufacturing scale among leading suppliers
Leading companies compete through portfolio breadth that spans professional point-of-care and home-use products. Manufacturing scale supports demand surges and reduces stockout risk, improving buyer confidence. The Covid Rapid Diagnostic Test Market also benefits from innovation in usability, packaging, and result readability that reduces user error and increases satisfaction. Suppliers with strong regulatory and quality systems can move faster across markets and channels.
Covid Rapid Diagnostic Test Market Challenges
The Covid Rapid Diagnostic Test Market faces demand volatility driven by changing infection waves, evolving guidance, and shifting consumer urgency. Inventory planning can be difficult when purchasing surges are short-lived and followed by prolonged normalization periods. Price pressure is common in retail channels where consumers compare alternatives, compressing margins for suppliers without differentiated value propositions. Procurement cycles in institutional channels can also shift rapidly during policy changes, impacting forecast stability.
For instance, Abbott’s BinaxNOW platform combined 15-minute results with its NAVICA digital workflow, while Abbott scaled U.S. production to 50 million tests per month, fulfilled the federal government’s initial 150 million-test order, and supported a 480,000-test procurement over six months for the University of Wisconsin System, underscoring how suppliers had to align technology deployment with abrupt swings in institutional and retail demand.
Performance expectations and regulatory requirements can raise development and compliance costs for manufacturers. Buyers increasingly expect clear evidence of reliable results and straightforward instructions for nonprofessional use. Product recalls, labeling issues, or inconsistent performance claims can quickly erode brand trust and trigger channel restrictions. Supply chain constraints and raw material availability can also disrupt continuity during sudden demand surges.
Covid Rapid Diagnostic Test Market Trends and Opportunities
Multiplex and respiratory-panel positioning is becoming more relevant as providers incorporate SARS-CoV-2 into broader seasonal respiratory testing. The Covid Rapid Diagnostic Test Market is seeing opportunities where testing solutions support triage decisions alongside influenza and RSV management pathways. Product design improvements that reduce user steps and improve readability can strengthen consumer confidence and repeat purchasing. Channel partnerships that integrate retail and digital distribution can also improve reach and reduce acquisition costs.
For instance, Roche’s cobas liat SARS-CoV-2, Influenza A/B & RSV assay can simultaneously differentiate SARS-CoV-2, influenza A, influenza B, and RSV from a single nasal or nasopharyngeal swab, with a sample-to-result time of about 20 minutes, which supports faster triage across COVID-19, influenza, and RSV care pathways.
Home-use adoption continues to create opportunities for subscription replenishment, household bundles, and employer-sponsored test access programs. The Covid Rapid Diagnostic Test Market can benefit from targeted products for high-risk populations and settings that require frequent screening. Data-enabled test ecosystems, including optional reporting tools and linkage to care pathways, may improve engagement where privacy and usability are addressed. Localization of production and diversified supplier bases can reduce regional fulfillment risk for large tenders.
Regional Insights
North America
North America accounted for 37.90% share in 2025, supported by strong retail penetration, established diagnostic purchasing behavior, and broad access through pharmacies and online channels. Health systems and employer programs continue to influence baseline demand for rapid testing. Regulatory clarity and the presence of large branded suppliers support product availability and channel confidence. Ongoing respiratory-season protocols keep rapid tests relevant for outpatient triage and household use.
Europe
Europe held 25.40% share in 2025, supported by mature diagnostics infrastructure and structured procurement approaches. Public health systems and institutional buyers continue to prioritize consistent quality documentation and predictable supply for outbreak response readiness. Retail distribution contributes to consumer access in major markets, while pharmacies remain a key channel for seasonal respiratory demand. Price sensitivity can be higher in tender-driven environments, shaping competitive dynamics.
Asia Pacific
Asia Pacific represented 24.10% share in 2025, supported by population scale and ongoing demand in dense urban centers where rapid screening supports continuity in schools and workplaces. Market heterogeneity shapes adoption across countries, with varied reimbursement and distribution maturity. Competitive intensity is often high due to regional manufacturing and pricing pressure. Demand remains resilient where institutional protocols and consumer convenience drive repeat purchasing.
Latin America
Latin America accounted for 6.90% share in 2025, with demand concentrated in major economies and urban markets where access and distribution are strongest. Procurement can be episodic and tied to public health priorities, creating uneven demand patterns. Retail access supports consumer purchasing, though affordability constraints can limit repeat testing outside surge periods. Supply continuity and distributor partnerships remain important for market expansion.
Middle East & Africa
Middle East & Africa held 5.70% share in 2025, reflecting a mix of stronger purchasing power in GCC markets and broader access constraints across parts of Africa. Public-sector tenders and donor-supported programs influence volumes in several markets. Distribution infrastructure and affordability shape the reach of home-use testing, while point-of-care demand remains relevant in clinical settings. Suppliers that can support reliable logistics and training tend to perform better across heterogeneous markets.
Competitive Landscape
Competition in the Covid Rapid Diagnostic Test Market is defined by brand credibility, portfolio breadth across professional and consumer products, and the ability to scale manufacturing during seasonal spikes. Leading companies emphasize regulatory positioning, quality systems, and channel reach across pharmacies, e-commerce, and institutional procurement. Differentiation is often achieved through ease of use, clarity of results, and supply reliability for large customers. Strategic partnerships with distributors and health systems also help suppliers improve adoption and maintain shelf presence.
Abbott maintains a strong position in rapid testing through broad channel access and product familiarity that supports consumer repeat purchases. Abbott’s approach is strengthened by scale in manufacturing and distribution, helping Abbott respond quickly to demand surges and maintain availability across retail and institutional channels. Abbott’s brand recognition also supports trust in self-testing contexts where consumers prioritize usability and confidence in results. Product portfolio breadth enables Abbott to serve both point-of-care and home-use needs within the Covid Rapid Diagnostic Test Market.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In January 2024, SEKISUI Diagnostics formalized an exclusive distribution agreement with Aptitude Medical Systems to sell the Aptitude Metrix COVID-19 Test in the U.S. The update is notable because the Metrix product was described as an EUA-approved molecular COVID-19 test that can use both swab and saliva samples and can be used by healthcare professionals or at home by consumers.
In June 2024, Roche announced that its four-in-one molecular test for SARS-CoV-2, Influenza A, Influenza B, and RSV received U.S. FDA Emergency Use Authorization. Roche said the test uses a single nasal-swab sample and can deliver results in about 20 minutes, expanding its molecular point-of-care testing portfolio for respiratory infections that include COVID-19.
In January 2024, WHO and the Medicines Patent Pool signed a licence agreement with SD Biosensor to enable sublicensees to manufacture SD Biosensor’s rapid diagnostic testing technology. This partnership matters for the COVID rapid diagnostics space because it is aimed at broadening manufacturing access for rapid diagnostic testing technology through licensed production.
Report Scope
Report Attribute
Details
Market size value in 2025
USD 5,214.79 million
Revenue forecast in 2032
USD 7,264.30 million
Growth rate (CAGR)
5.68% (2025–2032)
Base year
2025
Forecast period
2026–2032
Quantitative units
USD million
Segments covered
By Test Type; By Sample Type; By Format; By Use Setting; By Distribution Channel; By Regulatory Status
Regional scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Competition
15.5 Threat of New Entrants
15.6 Threat of Substitutes
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current size and forecast size of the Covid Rapid Diagnostic Test Market?
The Covid Rapid Diagnostic Test Market was valued at USD 5,214.79 million in 2025. The Covid Rapid Diagnostic Test Market is projected to reach USD 7,264.30 million by 2032.
What is the CAGR for the Covid Rapid Diagnostic Test Market during 2025–2032?
The Covid Rapid Diagnostic Test Market is projected to grow at a CAGR of 5.68%. The growth period covered is 2025–2032.
Which segment is the largest in the Covid Rapid Diagnostic Test Market?
Antigen is the largest segment by test type with a 64.20% share in 2025. The segment leads due to rapid turnaround time and broad suitability for decentralized testing.
What factors are driving growth in the Covid Rapid Diagnostic Test Market?
Growth is supported by decentralized testing demand across home-use and outpatient care. Omnichannel access through pharmacies and online purchasing supports repeat buying behavior.
Which companies are leading in the Covid Rapid Diagnostic Test Market?
Key companies include Abbott, Roche, Siemens Healthineers, BD, QuidelOrtho, SD Biosensor, Hologic, Thermo Fisher, Bio-Rad, and GenBody. Competition centers on scale, channel reach, regulatory positioning, and portfolio breadth.
Which region leads the Covid Rapid Diagnostic Test Market?
North America leads with a 37.90% share in 2025. Regional leadership is supported by established retail distribution and strong access to diagnostics.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The global Colposcopy Devices Market size was estimated at USD 606.81 million in 2025 and is expected to reach USD 862 million by 2032, growing at a CAGR of 5.14% from 2025 to 2032.
The global Collagen Dressings Market size was estimated at USD 2,332 million in 2025 and is expected to reach USD 3,631 million by 2032, growing at a CAGR of 6.53% from 2025 to 2032.
The global Cart Based Conventional Breast Ultrasound Systems Market size was estimated at USD 333.38 million in 2025 and is expected to reach USD 485 million by 2032, growing at a CAGR of 5.5% from 2025 to 2032.
The global Cardiovascular Ultrasound System Market size was estimated at USD 2008 million in 2025 and is expected to reach USD 2857 million by 2032, growing at a CAGR of 5.17% from 2025 to 2032.
The global Cartilage Repair Regeneration Market size was estimated at USD 6,251 million in 2025 and is expected to reach USD 8,737 million by 2032, growing at a CAGR of 4.9% from 2025 to 2032.
The global Chromatography Instrumentation Market size was estimated at USD 10,149 million in 2025 and is expected to reach USD 14,941 million by 2032, growing at a CAGR of 5.68% from 2025 to 2032.
The global Cast Saw Devices Market size was estimated at USD 189.31 million in 2025 and is expected to reach USD 259 million by 2032, growing at a CAGR of 4.59% from 2025 to 2032.
The global Cardiac Surgery Instruments Market size was estimated at USD 2,169 million in 2025 and is expected to reach USD 3,839 million by 2032, growing at a CAGR of 8.5% from 2025 to 2032.
The global Cerebrospinal Fluid Management Market size was estimated at USD 1932 million in 2025 and is expected to reach USD 2848.24 million by 2032, growing at a CAGR of 5.7% from 2025 to 2032.
The global Cell Proliferation Kit Market size was estimated at USD 735 million in 2025 and is expected to reach USD 1,574.75 million by 2032, growing at a CAGR of 11.5% from 2025 to 2032.
The global Cardiovascular devices market size was estimated at USD 57,768 million in 2025 and is expected to reach USD 96,466.25 million by 2032, growing at a CAGR of 7.6% from 2025 to 2032.
The global Cardiac rhythm management devices market size was estimated at USD 22035 million in 2025 and is expected to reach USD 33461.51 million by 2032, growing at a CAGR of 6.15% from 2025 to 2032.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
